Core Insights - The stock price of Burning Stone Medical (BNR) increased by 2.31% to $6.295 per share, with a total market capitalization of $67.7757 million as of August 5 [1] - As of March 31, 2025, the total revenue of Burning Stone Medical reached 133 million RMB, representing a year-on-year growth of 5.94%, while the net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] - The company is set to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual date subject to company announcements [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company's business and research directions primarily cover: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, Burning Stone Medical received the first certification for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the field of in vitro diagnostics [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Viewpoint - On August 5, 2023, Burning Stone Medical (BNR) experienced an 8.51% increase in stock price, reaching $6.153 per share, with a total market capitalization of $66.2447 million [1] Financial Performance - As of March 31, 2025, Burning Stone Medical reported total revenue of 133 million RMB, reflecting a year-on-year growth of 5.94% [1] - The company recorded a net profit attributable to shareholders of -13.5 million RMB, showing a significant year-on-year improvement of 88.89% [1] Company Overview - Burning Stone Medical, established in 2014, focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology [2] - The company has a leading market share in tumor patient detection in China and collaborates with global anti-tumor pharmaceutical companies on biomarkers and companion diagnostics [2] - The company received the first NGS testing kit approval from the National Medical Products Administration (NMPA) in July 2018, marking a milestone in the in vitro diagnostic field [2] - The laboratories in Guangzhou, China, and California, USA, have obtained CLIA and CAP laboratory quality system certifications, ensuring high standards in testing [2] - The company aims to continue developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

8月4日，燃石医学(BNR)盘中上涨5.11%，截至22:00，报5.96美元/股，成交3338.0美元，总市值6416.89 万美元。 财务数据显示，截至2025年03月31日，燃石医学收入总额1.33亿人民币，同比增长5.94%；归母净利 润-1350.0万人民币，同比增长88.89%。 大事提醒： 8月28日，燃石医学将披露2025财年中报（数据来源于纳斯达克官网，预计披露日期为美国当地时间， 实际披露日期以公司公告为准）。 资料显示，燃石医学有限责任公司成立于2014年,公司使命为"用科学守护生命之光", 专注于为肿瘤精准 医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1)肿瘤患病人群检测,在 中国拥有领先的市场份额;2)全球抗肿瘤药企的生物标志物和伴随诊断合作;3)多癌种早检。 燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊 断领域具有里程碑式意义。位于中国广州的实验室通过广东省临床检验中心颁发的"高通量测序实验 室"技术审核,获得美国CLIA和CAP实验室质量体系资质认证;位于美国加利福尼亚州的实验室也已获得 CL ...

Group 1 - The stock price of Burning Stone Medical (BNR) opened up by 11.36% on July 31, reaching $6.47 per share, with a total market capitalization of $69.66 million [1] - As of March 31, 2025, Burning Stone Medical reported total revenue of 133 million RMB, representing a year-on-year growth of 5.94%, while the net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] Group 2 - Burning Stone Medical is set to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual disclosure date subject to company announcement [2] - Founded in 2014, Burning Stone Medical focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, holding a leading market share in tumor patient detection in China [2] - The company received the first NGS testing kit approval from the National Medical Products Administration (NMPA) in July 2018, marking a milestone in the in vitro diagnostic field [2] - The laboratories in Guangzhou, China, and California, USA, have obtained CLIA and CAP laboratory quality system certifications, ensuring high standards in their operations [2] - Burning Stone Medical aims to continue developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 5.51% on July 30, reaching $6.13 per share, with a total market capitalization of $65.99 million [1] - As of March 31, 2025, the company's total revenue was 133 million RMB, reflecting a year-on-year growth of 5.94%, while the net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] - Burning Stone Medical is set to disclose its mid-year report for the fiscal year 2025 on August 28 [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company's business and research directions primarily cover: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, Burning Stone Medical received the first certificate for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the field of in vitro diagnostics [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Viewpoint - BNR (Burning Rock Biotech) shows positive financial growth with a revenue increase and a significant reduction in net loss, indicating potential for investment opportunities in the precision oncology market [1][2]. Financial Performance - As of March 31, 2025, BNR reported total revenue of 133 million RMB, representing a year-on-year growth of 5.94% [1]. - The net loss attributable to the parent company was 13.5 million RMB, which reflects a year-on-year improvement of 88.89% [1]. Upcoming Events - BNR is scheduled to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual date subject to company announcement [1]. Company Background - Founded in 2014, BNR focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [1]. - The company has a leading market share in tumor patient testing in China and collaborates with global anti-tumor pharmaceutical companies on biomarkers and companion diagnostics [1]. Regulatory Milestones - In July 2018, BNR received the first NGS testing kit approval from the National Medical Products Administration (NMPA) in China, marking a significant milestone in the in vitro diagnostic field [2]. - BNR's laboratories in Guangzhou and California have obtained CLIA and CAP laboratory quality system certifications, ensuring high standards in their testing processes [2].

燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊 断领域具有里程碑式意义。位于中国广州的实验室通过广东省临床检验中心颁发的"高通量测序实验 室"技术审核,获得美国CLIA和CAP实验室质量体系资质认证;位于美国加利福尼亚州的实验室也已获得 CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准 医疗领域的发展。 本文源自：金融界 作者：行情君 7月28日，燃石医学(BNR)开盘上涨4.41%，截至21:34，报7.1美元/股，成交8602.0美元，总市值7644.28 万美元。 财务数据显示，截至2025年03月31日，燃石医学收入总额1.33亿人民币，同比增长5.94%；归母净利 润-1350.0万人民币，同比增长88.89%。 大事提醒： 8月28日，燃石医学将披露2025财年中报（数据来源于纳斯达克官网，预计披露日期为美国当地时间， 实际披露日期以公司公告为准）。 资料显示，燃石医学有限责任公司成立于2014年,公司使命为"用科学守护生命之光", 专注于为肿瘤精准 医疗提供具有临床价值的二代基因测序(NGS ...

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 2.81% to $3.66 per share, with a total market capitalization of approximately $39.41 million as of July 8 [1] - For the fiscal year ending March 31, 2025, the company reported total revenue of 133 million RMB, reflecting a year-on-year growth of 5.94%, while the net profit attributable to shareholders was -13.5 million RMB, showing a significant year-on-year improvement of 88.89% [1] - Burning Stone Medical is set to release its mid-year report for the fiscal year 2025 on August 28, with the actual disclosure date subject to company announcements [1] Company Overview - Founded in 2014, Burning Stone Medical focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [1] - The company's business and research directions include: 1) detection for cancer patients, holding a leading market share in China; 2) collaborations with global anti-cancer pharmaceutical companies for biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, Burning Stone Medical received the first NGS testing kit certification for tumors from the National Medical Products Administration (NMPA) in China, marking a significant milestone in the in vitro diagnostic field [2] - The laboratory in Guangzhou has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP in the United States [2] - The laboratory located in California has also received CLIA and CAP certifications, indicating the company's commitment to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 7.38% on June 5, reaching $3.2 per share, with a total market capitalization of $34.45 million [1] - As of December 31, 2024, the company's total revenue is projected to be 516 million RMB, a year-on-year decrease of 4.02%, while the net profit attributable to the parent company is expected to be -347 million RMB, reflecting a year-on-year increase of 46.97% [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "protect the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [2] - The company's business and research directions primarily cover: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [2] - The company received the first NGS testing kit certification for tumors from the National Medical Products Administration (NMPA) in July 2018, marking a milestone in the field of in vitro diagnostics [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Viewpoint - The company, Burning Stone Medical (BNR), is experiencing fluctuations in its stock price and financial performance, with a notable decrease in revenue but an increase in net profit year-over-year [1][2]. Financial Performance - As of December 31, 2024, Burning Stone Medical reported total revenue of 516 million RMB, a year-over-year decrease of 4.02% [1]. - The company recorded a net profit attributable to shareholders of -347 million RMB, which represents a year-over-year increase of 46.97% [1]. Upcoming Events - Burning Stone Medical is scheduled to disclose its Q1 2025 financial report on June 4, with the actual date subject to company announcements [2]. Company Overview - Founded in 2014, Burning Stone Medical focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology [2]. - The company holds a leading market share in tumor patient testing in China and collaborates with global anti-tumor pharmaceutical companies on biomarkers and companion diagnostics [2]. - The company received the first NGS testing kit certification from the National Medical Products Administration (NMPA) in July 2018, marking a significant milestone in the in vitro diagnostic field [2]. - Its laboratories in Guangzhou and California have obtained CLIA and CAP laboratory quality system certifications, ensuring high standards in testing [2].